Observational Disease Registry of Patients Treated with
Systemic Mold-Active Triazoles

Principal Investigator

Joseph Bubalo

Study Purpose

This is an observational research study of treatment that is usually given patients who have been diagnosed with an invasive fungal infection or patients who are at risk and are being treated to prevent an invasive fungal infection. Information from medical records is used to learn more about how these patients are treated and how they respond to treatment. It is thought that collecting this information may help researchers and doctors to determine the best treatment options and improve patient care for people who are at risk for fungal infections, or who have invasive fungal infections.

Medical Condition(s)

Immune compromised patients at risk for fungal infection
Patients with fungal infections
mold-active triazole
anti-fungal medication

Eligibility Criteria

Patients must be taking or will soon be taking a target antifungal drug: voriconazole (VFEND), isavuconazium sulfate (Cresemba), or posaconasole (Noxafil).
Patients must be 18 or older
Patients can't be in a study with an investigational antifungal drug

Age Range

18 - 89

Healthy Volunteers Needed


Duration of Participation

Patients will be followed until 90 days after your last dose of antifungal medication.

Minors Included



Knight Cancer Intake Center: (503)494-7999
Clinical Trials Information Line: (503)­494-­1080 or


Astellas Pharma Global Development, Inc.

Recruitment End


Compensation Provided


Go Back